메뉴 건너뛰기




Volumn 6, Issue 7, 2013, Pages e201303017-

The Innovative Medicines Initiative: A public private partnership model to foster drug discovery

Author keywords

Attrition rate; Bottlenecks; Drug efficacy; Drug safety; Knowledge management; Pharmaceutical industry

Indexed keywords


EID: 84902190409     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.5936/csbj.201303017     Document Type: Article
Times cited : (28)

References (67)
  • 1
    • 73449101512 scopus 로고    scopus 로고
    • Lessons from 60 years of pharmaceutical innovation
    • Munos B. (2009) Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 12:959-968.
    • (2009) Nat. Rev. Drug Discov , vol.12 , pp. 959-968
    • Munos, B.1
  • 2
    • 84055214441 scopus 로고    scopus 로고
    • Economist Intelligence Unit (2011) The future of healthcare in Europe. http://www.janssen-emea.com/sites/default/files/The-Future-Of-Healthcare-In- Europe.pdf
    • (2011) The Future of Healthcare in Europe
  • 3
    • 84865677102 scopus 로고    scopus 로고
    • From sick care to health care-reengineering prevention into the U. S. System
    • Marvasti F, Stafford RS. (2012) From sick care to health care-reengineering prevention into the U. S. system. N Engl J Med. 367(10):889-891
    • (2012) N Engl J Med , vol.367 , Issue.10 , pp. 889-891
    • Marvasti, F.1    Stafford, R.S.2
  • 4
    • 4344645978 scopus 로고    scopus 로고
    • Can the pharmaceutical industry reduce attrition rates?
    • Kola I, Landis J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715. (Pubitemid 39173511)
    • (2004) Nature Reviews Drug Discovery , vol.3 , Issue.8 , pp. 711-715
    • Kola, I.1    Landis, J.2
  • 6
    • 57649119801 scopus 로고    scopus 로고
    • Requirements for a lead compound to become a clinical candidate
    • Hefti FF (2008) Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 9 Suppl 3:S7.
    • (2008) BMC Neurosci , vol.9 , Issue.SUPPL. 3
    • Hefti, F.F.1
  • 9
    • 77955652343 scopus 로고    scopus 로고
    • Reaping the benefits of biomedical research: Partnerships required
    • Portilla LM, Alving B (2010) Reaping the benefits of biomedical research: partnerships required. Sci Transl Med. 2(35):35cml7
    • (2010) Sci Transl Med , vol.2 , Issue.35
    • Portilla, L.M.1    Alving, B.2
  • 10
    • 84877120013 scopus 로고    scopus 로고
    • Improving R&D productivity of pharmaceutical companies through public-private partnership: Experiences from the Innovative Medicines Initiative
    • Laverty H, Gunn M, Goldman M. (2012) Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative. Expert Rev. Pharmacoecon & Outcomes Res 12(5):545-548
    • (2012) Expert Rev. Pharmacoecon & Outcomes Res , vol.12 , Issue.5 , pp. 545-548
    • Laverty, H.1    Gunn, M.2    Goldman, M.3
  • 11
    • 67349124872 scopus 로고    scopus 로고
    • The global portfolio of new antimalarial medicines under development
    • Olliaro P, Wells T N C (2009) The Global Portfolio of New Antimalarial Medicines Under Development. Clin. Pharmacol. Ther 85(6):584-595
    • (2009) Clin. Pharmacol. Ther , vol.85 , Issue.6 , pp. 584-595
    • Olliaro, P.1    Wells, T.N.C.2
  • 12
    • 84866739808 scopus 로고    scopus 로고
    • Drug discovery in pharmaceutical industry: Productivity challenges and trends
    • Khanna I (2012) Drug discovery in pharmaceutical industry: productivity challenges and trends, Drug Discov. Today 17(19-20):1088-102
    • (2012) Drug Discov. Today , vol.17 , Issue.19-20 , pp. 1088-1102
    • Khanna, I.1
  • 13
    • 84878488692 scopus 로고    scopus 로고
    • Public-private partnerships as driving forces in the quest for innovative medicines
    • Goldman M, Compton C, Mittleman BB (2013) Public-private partnerships as driving forces in the quest for innovative medicines. Clin Transl Med. 2(1):2.
    • (2013) Clin Transl Med , vol.2 , Issue.1 , pp. 2
    • Goldman, M.1    Compton, C.2    Mittleman, B.B.3
  • 14
    • 39649084919 scopus 로고    scopus 로고
    • The FDA critical path initiative and its influence on new drug development
    • DOI 10.1146/annurev.med.59.090506.155819
    • Woodcock J, Woosley R (2008) The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1-12. (Pubitemid 351287920)
    • (2008) Annual Review of Medicine , vol.59 , pp. 1-12
    • Woodcock, J.1    Woosley, R.2
  • 15
    • 57649120069 scopus 로고    scopus 로고
    • NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders
    • Brady LS, Winsky L, Goodman W, Oliveri ME, Stover E (2009) NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacol. 34(1):229-43.
    • (2009) Neuropsychopharmacol , vol.34 , Issue.1 , pp. 229-243
    • Brady, L.S.1    Winsky, L.2    Goodman, W.3    Oliveri, M.E.4    Stover, E.5
  • 16
    • 84857237851 scopus 로고    scopus 로고
    • The innovative medicines initiative: A European response to the innovation challenge
    • Goldman M (2012) The innovative medicines initiative: a European response to the innovation challenge. Clin Pharmacol Ther. 91(3):4l8-25.
    • (2012) Clin Pharmacol Ther , vol.91 , Issue.3
    • Goldman, M.1
  • 17
    • 77951494873 scopus 로고    scopus 로고
    • Targeted cancer therapies in the twenty-first century: Lessons from imatinib
    • Stegmeier F, Warmuth M, Sellers WR, Dorsch M. (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 87(5):543-52.
    • (2010) Clin Pharmacol Ther , vol.87 , Issue.5 , pp. 543-552
    • Stegmeier, F.1    Warmuth, M.2    Sellers, W.R.3    Dorsch, M.4
  • 18
    • 84875448716 scopus 로고    scopus 로고
    • Phenotypic vs. Target-based drug discovery for first-in-class medicines
    • Swinney DC. (2013) Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther 93(4):299-301.
    • (2013) Clin Pharmacol Ther , vol.93 , Issue.4 , pp. 299-301
    • Swinney, D.C.1
  • 19
    • 84875471298 scopus 로고    scopus 로고
    • Systems-based discovery advances drug development
    • Waldman SA, Terzic A (2013) Systems-based discovery advances drug development. Clin Pharmacol Ther 93(4):285-7.
    • (2013) Clin Pharmacol Ther , vol.93 , Issue.4 , pp. 285-287
    • Waldman, S.A.1    Terzic, A.2
  • 20
    • 84871277043 scopus 로고    scopus 로고
    • Solving the lost in translation problem: Improving the effectiveness of translational research
    • Ergorul C, Levin LA (2013) Solving the lost in translation problem: improving the effectiveness of translational research. Curr Opin Pharmacol 13(1):108-14.
    • (2013) Curr Opin Pharmacol , vol.13 , Issue.1 , pp. 108-114
    • Ergorul, C.1    Levin, L.A.2
  • 22
    • 80055088241 scopus 로고    scopus 로고
    • Believe it or not: How much can we rely on published data on potential drug targets?
    • Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 10(9):712
    • (2011) Nat Rev Drug Discov , vol.10 , Issue.9 , pp. 712
    • Prinz, F.1    Schlange, T.2    Asadullah, K.3
  • 23
    • 84859169880 scopus 로고    scopus 로고
    • Drug development: Raise standards for preclinical cancer research
    • Begley CG, Ellis LM (2012) Drug development: Raise standards for preclinical cancer research. Nature 483(7391):531-3.
    • (2012) Nature , vol.483 , Issue.7391 , pp. 531-533
    • Begley, C.G.1    Ellis, L.M.2
  • 24
    • 84933675226 scopus 로고    scopus 로고
    • Deep impact: Unintended consequences of journal rank
    • Brembs B, Button K, Munafo M (2013) Deep impact: unintended consequences of journal rank. Front Hum Neurosci. 7:291
    • (2013) Front Hum Neurosci , vol.7 , pp. 291
    • Brembs, B.1    Button, K.2    Munafo, M.3
  • 25
    • 0035856920 scopus 로고    scopus 로고
    • Global and societal implications of the diabetes epidemic
    • DOI 10.1038/414782a
    • Zimmet P, Alberti K G MM, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 404:782-787 (Pubitemid 34000780)
    • (2001) Nature , vol.414 , Issue.6865 , pp. 782-787
    • Zimmet, P.1    Alberti, K.G.M.M.2    Shaw, J.3
  • 27
    • 84864378869 scopus 로고    scopus 로고
    • Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy
    • Williams WW, Salem RM, McKnight AJ, Sandholm N, Forsblom C et al (2012) Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy. Diabetes 61(8):2187-2194
    • (2012) Diabetes , vol.61 , Issue.8 , pp. 2187-2194
    • Williams, W.W.1    Salem, R.M.2    McKnight, A.J.3    Sandholm, N.4    Forsblom, C.5
  • 28
  • 30
    • 84867854875 scopus 로고    scopus 로고
    • Bag of Naive Bayes: Biomarker selection and classification from genome-wide SNP data
    • Sambo F, Trifoglio E, Di Camillo B, Toffolo GM, Cobelli C (2012) Bag of Naive Bayes: biomarker selection and classification from genome-wide SNP data. BMC Bioinformatics 13 Suppl 14:S2.
    • (2012) BMC Bioinformatics , vol.13 , Issue.SUPPL. 14
    • Sambo, F.1    Trifoglio, E.2    Di Camillo, B.3    Toffolo, G.M.4    Cobelli, C.5
  • 31
    • 79959682988 scopus 로고    scopus 로고
    • Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein BlOO-only mice
    • Heinonen SE, Merentie M, Hedman M, Makinen PI, Loponen E, et al (2011) Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein BlOO-only mice. Cardiovasc Diabetol 10:59.
    • (2011) Cardiovasc Diabetol , vol.10 , pp. 59
    • Heinonen, S.E.1    Merentie, M.2    Hedman, M.3    Makinen, P.I.4    Loponen, E.5
  • 32
    • 33645231857 scopus 로고    scopus 로고
    • Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment
    • Breivik H, Collett B, Ventafridda V, Cohen R, et Al (2006) Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment, Eur. J. Pain 10(4):287
    • (2006) Eur. J. Pain , vol.10 , Issue.4 , pp. 287
    • Breivik, H.1    Collett, B.2    Ventafridda, V.3    Cohen, R.4
  • 33
    • 40849119571 scopus 로고    scopus 로고
    • Predictive validity of animal pain models? A comparison of the pharmacokineticpharmacodynamic relationship for pain drugs in rats and humans
    • Whiteside GT, Adedoyin A, Leventhal L (2008) Predictive validity of animal pain models? A comparison of the pharmacokineticpharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacol 54(5):767-75.
    • (2008) Neuropharmacol , vol.54 , Issue.5 , pp. 767-775
    • Whiteside, G.T.1    Adedoyin, A.2    Leventhal, L.3
  • 34
    • 84875412180 scopus 로고    scopus 로고
    • The pattern and time course of somatosensory changes in the human UVB sunburn model reveal the presence of peripheral and central sensitization
    • Gustorff B, Sychab T, Lieba-Samala D, Rolkec R, Treede RD, et al (2013) The pattern and time course of somatosensory changes in the human UVB sunburn model reveal the presence of peripheral and central sensitization Pain 154(4):586-597
    • (2013) Pain , vol.154 , Issue.4 , pp. 586-597
    • Gustorff, B.1    Sychab, T.2    Lieba-Samala, D.3    Rolkec, R.4    Treede, R.D.5
  • 38
    • 65449119595 scopus 로고    scopus 로고
    • Economic cost of autism in the UK
    • Knapp M, Romeo R, Beecham J (2009) Economic cost of autism in the UK. Autism 13(3):317-336.
    • (2009) Autism , vol.13 , Issue.3 , pp. 317-336
    • Knapp, M.1    Romeo, R.2    Beecham, J.3
  • 39
    • 84902202442 scopus 로고    scopus 로고
    • http://www.sagecrossingfoundation.org/pdfs/Economic-Impact-of-Adut- Autism-2014-2028.pdf
  • 40
    • 84884211527 scopus 로고    scopus 로고
    • Translational approaches to the biology of Autism: False dawn or a new era?
    • Ecker C, Spooren W, Murphy D (2013) Translational approaches to the biology of Autism: false dawn or a new era? Mol Psychiatry 18(4):435-42.
    • (2013) Mol Psychiatry , vol.18 , Issue.4 , pp. 435-442
    • Ecker, C.1    Spooren, W.2    Murphy, D.3
  • 41
    • 84856092811 scopus 로고    scopus 로고
    • Networking in Autism: Leveraging genetic, biomarker and model system findings in the search for new treatments
    • Veenstra-VanderWeele J, Blakely RD (2012) Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New Treatments Neuropsychopharmacology. 37(1):196-212.
    • (2012) Neuropsychopharmacology , vol.37 , Issue.1 , pp. 196-212
    • Veenstra-VanderWeele, J.1    Blakely, R.D.2
  • 42
    • 84868338744 scopus 로고    scopus 로고
    • EU-AIMS: A boost to autism research
    • Murphy D, Spooren W, (2012) EU-AIMS: a boost to autism research. Nat. Rev Drug Discov. 11:815-816
    • (2012) Nat. Rev Drug Discov , vol.11 , pp. 815-816
    • Murphy, D.1    Spooren, W.2
  • 43
    • 67650750977 scopus 로고    scopus 로고
    • A synaptic trek to autism
    • Bourgeron T (2009) A synaptic trek to autism. Curr Opin Neurobiol. 19(2):231-4.
    • (2009) Curr Opin Neurobiol , vol.19 , Issue.2 , pp. 231-234
    • Bourgeron, T.1
  • 44
    • 77957912870 scopus 로고    scopus 로고
    • The genetics of child psychiatric disorders: Focus on autism and Tourette syndrome
    • State MW (2010) The genetics of child psychiatric disorders: focus on autism and Tourette syndrome. Neuron 68(2):254-69
    • (2010) Neuron , vol.68 , Issue.2 , pp. 254-269
    • State, M.W.1
  • 45
    • 84865208871 scopus 로고    scopus 로고
    • Rate of de novo mutations and the importance of father's age to disease risk
    • Kong A, Frig ML, Masson G, Besenbacher S, Sulem P, et al (2012) Rate of de novo mutations and the importance of father's age to disease risk Nature 4(8):471-475
    • (2012) Nature , vol.4 , Issue.8 , pp. 471-475
    • Kong, A.1    Frig, M.L.2    Masson, G.3    Besenbacher, S.4    Sulem, P.5
  • 46
    • 79952313620 scopus 로고    scopus 로고
    • Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting
    • Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting Brain Res 1380:42-77
    • (2011) Brain Res , vol.1380 , pp. 42-77
    • Betancur, C.1
  • 47
    • 84862659562 scopus 로고    scopus 로고
    • Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities
    • doi:pii: a009886
    • Zoghbi HY, Bear MF (2012) Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4(3): doi:pii: a009886
    • (2012) Cold Spring Harb. Perspect. Biol. , vol.4 , Issue.3
    • Zoghbi, H.Y.1    Bear, M.F.2
  • 48
    • 84867229875 scopus 로고    scopus 로고
    • Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism
    • Baudoin SJ, Gaudias J, Gerharz S, Jatstatt L, Zhou K, et al (2012) Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism. Science 338 (6103) :128-132
    • (2012) Science , vol.338 , Issue.6103 , pp. 128-132
    • Baudoin, S.J.1    Gaudias, J.2    Gerharz, S.3    Jatstatt, L.4    Zhou, K.5
  • 49
    • 33847638137 scopus 로고    scopus 로고
    • Estimates of the cancer incidence and mortality in Europe in 2006
    • DOI 10.1093/annonc/mdl498
    • Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol. 18(3):581-592. (Pubitemid 46359643)
    • (2007) Annals of Oncology , vol.18 , Issue.3 , pp. 581-592
    • Ferlay, J.1    Autier, P.2    Boniol, M.3    Heanue, M.4    Colombet, M.5    Boyle, P.6
  • 50
    • 84902184789 scopus 로고    scopus 로고
    • Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery
    • in press
    • Ruggeri BA, Camp F. (2013) Animal Models of Disease: Pre-clinical Animal Models of Cancer and Their Applications and Utility in Drug Discovery. Biochem Pharmacol, in press.
    • (2013) Biochem Pharmacol
    • Ruggeri, B.A.1    Camp, F.2
  • 51
    • 78149284767 scopus 로고    scopus 로고
    • RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
    • Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107
    • (2010) Nature , vol.468 , pp. 103-107
    • Gonzalez-Suarez, E.1    Jacob, A.P.2    Jones, J.3    Miller, R.4    Roudier-Meyer, M.P.5
  • 52
    • 78649821635 scopus 로고    scopus 로고
    • Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression
    • Mukherjee A, Soyal SM, Li J, Ying Y, He B, et al (2010) Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. FASEB J. 24:4408-4419
    • (2010) FASEB J , vol.24 , pp. 4408-4419
    • Mukherjee, A.1    Soyal, S.M.2    Li, J.3    Ying, Y.4    He, B.5
  • 53
    • 84864742990 scopus 로고    scopus 로고
    • Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis
    • Sutton EE, Riche DM (2012) Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 46(7-8):1000-1009
    • (2012) Ann Pharmacother , vol.46 , Issue.7-8 , pp. 1000-1009
    • Sutton, E.E.1    Riche, D.M.2
  • 55
    • 84881360676 scopus 로고    scopus 로고
    • In silico ADMET prediction: Recent advances, current challenges and future trends
    • Cheng F, Li W, Liu G, Tang Y (2013) In Silico ADMET Prediction: Recent Advances, Current Challenges and Future Trends. Curr Top Med Chem 13(11):1273-1289.
    • (2013) Curr Top Med Chem , vol.13 , Issue.11 , pp. 1273-1289
    • Cheng, F.1    Li, W.2    Liu, G.3    Tang, Y.4
  • 56
    • 84883451066 scopus 로고    scopus 로고
    • Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities
    • In press
    • Sutter A, Amberg A, Boyer S, Brigo A, Contrera JF, et al (2013) Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul Toxicol Pharmacol. In press.
    • (2013) Regul Toxicol Pharmacol
    • Sutter, A.1    Amberg, A.2    Boyer, S.3    Brigo, A.4    Contrera, J.F.5
  • 57
    • 84873048924 scopus 로고    scopus 로고
    • The eTOX library of public resources for in silico toxicity prediction
    • Cases M, Pastor M, Sanz F. (2013), The eTOX Library of Public Resources for in Silico Toxicity Prediction. Mol. Inf., 32:24-35
    • (2013) Mol. Inf. , vol.32 , pp. 24-35
    • Cases, M.1    Pastor, M.2    Sanz, F.3
  • 58
    • 79952159586 scopus 로고    scopus 로고
    • A multiscale simulation system for the prediction of drug-induced cardiotoxicity
    • Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M (2011) A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J Chem Inf Model. 51(2):483-92
    • (2011) J Chem Inf Model , vol.51 , Issue.2 , pp. 483-492
    • Obiol-Pardo, C.1    Gomis-Tena, J.2    Sanz, F.3    Saiz, J.4    Pastor, M.5
  • 59
    • 84857979437 scopus 로고    scopus 로고
    • Application of data mining and visualization techniques for the prediction of drug-induced nausea in man
    • Parkinson J, Muthas D, Clark M, Boyer S, Valentin JP, et al (2012) Application of data mining and visualization techniques for the prediction of drug-induced nausea in man. Toxicol Sci. 126(1):275-84
    • (2012) Toxicol Sci , vol.126 , Issue.1 , pp. 275-284
    • Parkinson, J.1    Muthas, D.2    Clark, M.3    Boyer, S.4    Valentin, J.P.5
  • 60
    • 84883246246 scopus 로고    scopus 로고
    • Scientific competency questions as the basis for semantically enriched open pharmacological space development
    • in Press
    • Azzaoui K, Jacoby E, Senger S, Rodriguez EC, Loza M, et al (2013) Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discov Today. In Press
    • (2013) Drug Discov Today
    • Azzaoui, K.1    Jacoby, E.2    Senger, S.3    Rodriguez, E.C.4    Loza, M.5
  • 61
    • 84875166951 scopus 로고    scopus 로고
    • European lead factory opens for business
    • Mullard A (2013) European lead factory opens for business. Nat Rev Drug Discov. 12(3):173-5.
    • (2013) Nat Rev Drug Discov , vol.12 , Issue.3 , pp. 173-175
    • Mullard, A.1
  • 62
    • 67650506936 scopus 로고    scopus 로고
    • Open access chemical and clinical probes to support drug discovery
    • Edwards AM, Bountra C, Kerr DJ, Willson TM (2009) Open access chemical and clinical probes to support drug discovery. Nat Chem Biol. 5(7):436-40
    • (2009) Nat Chem Biol , vol.5 , Issue.7 , pp. 436-440
    • Edwards, A.M.1    Bountra, C.2    Kerr, D.J.3    Willson, T.M.4
  • 64
    • 33748325882 scopus 로고    scopus 로고
    • Drug-target residence time and its implications for lead optimization
    • DOI 10.1038/nrd2082, PII NRD2082
    • Copeland, RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739. (Pubitemid 44323700)
    • (2006) Nature Reviews Drug Discovery , vol.5 , Issue.9 , pp. 730-739
    • Copeland, R.A.1    Pompliano, D.L.2    Meek, T.D.3
  • 65
    • 58449131873 scopus 로고    scopus 로고
    • The role of binding kinetics in therapeutically useful drug action
    • Swinney DC (2009) The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 12:31-39
    • (2009) Curr Opin Drug Discov Devel , vol.12 , pp. 31-39
    • Swinney, D.C.1
  • 66
    • 67649973722 scopus 로고    scopus 로고
    • The importance of drug-target residence time
    • Zhang R, Monsma F (2009) The importance of drug-target residence time. Curr Opin Drug Discov Devel 12:488-96.
    • (2009) Curr Opin Drug Discov Devel , vol.12 , pp. 488-496
    • Zhang, R.1    Monsma, F.2
  • 67
    • 33646122469 scopus 로고    scopus 로고
    • Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: Mechanisms leading to optimal efficacy and safety
    • Swinney DC (2006) Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 6:461-478.
    • (2006) Curr Top Med Chem , vol.6 , pp. 461-478
    • Swinney, D.C.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.